07:00 , Oct 3, 2016 |  BC Week In Review  |  Clinical News

Afluria Quadrivalent: Phase III data

CSL’s Seqirus unit reported data from a double-blind, U.S. Phase III trial in 3,484 adults ages >=18 showing that intramuscular Afluria Quadrivalent met the primary endpoint of non-inferiority to Afluria trivalent influenza vaccine and a...
07:00 , Oct 3, 2016 |  BC Week In Review  |  Clinical News

Afluria Quadrivalent: Phase III data

CSL’s Seqirus unit reported data from a double-blind, U.S. Phase III trial in 2,278 children ages 5-17 showing that intramuscular Afluria Quadrivalent met the primary endpoint of non-inferior immunogenicity to Fluarix Quadrivalent as assessed...
07:00 , Sep 5, 2016 |  BC Week In Review  |  Clinical News

Afluria Quadrivalent regulatory update

FDA approved an sBLA from CSL’s Seqirus unit for Afluria Quadrivalent to prevent infection from 2 influenza subtypes A and 2 influenza type B viruses contained in the vaccine in people ages >=18. Seqirus said...